Bitcoin 681.54
$32,553.00 2.09363%
Ethereum 38.96
$1,239.06 3.14395%
XRP 0.00
$0.27 -0.78245%
Zcash 0.07
$88.36 0.084%
Monero 0.23
$137.79 0.16631%
Tether 0.00
$1.00 0.14206%
Elite 0.00
$0.00 -48.25623%
Developing a suite of Class Leading Immunotherapeutics
Token sale completed on 22 February
Goal: Not set
Website Whitepaper

Xeophin has devised a funding pathway to develop the XeRA-1 Therapeutic for Rheumatoid Arthritis, however this offering represents much more than stake in a promising pharmaceutical. Xeophins’ unique approach to Biotech funding can change the paradigm of how medicine is financed. Xeophin is tokenizing 50% of the future royalties generated by XeRA-1, allowing its’ token holders to fund, and benefit from its’ success. Our mission is to take our core technologies and drive them through our six step process. The outcome being a transaction-ready and IP protected technology portfolio, tokenized. From then on, Xeophin will undertake commercialization activities to achieve a significant royalty deal, delivering value to our XeRA-1 Token holders. Being backed by a physical asset, the XeRA-1 Arthritis Therapeutic, the XERA1 token can increase in value as milestones are hit on the road to commercialization. Once live, token holders will yield cash royalty payments, commensurate to XeRA-1s’ earnings.

Token Sale: 20 August — 22 February
ICO Token Price
Min/Max Personal Cap

Add a comment

Member of The Internet Defense League